COMMUNIQUÉS West-GlobeNewswire

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
17/06/2025
Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform insights into the [...]
Alira Health Launches Patient Engagement Certification for Life Sciences Organizations
17/06/2025
FRAMINGHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Alira Health is a global healthcare consultancy that helps life sciences companies deliver patient-centered solutions through integrated clinical, strategic, and [...]
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
17/06/2025
U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseases Capricor remains on track for the August 31, 2025, PDUFA date [...]
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
17/06/2025
$452.5 million in total milestone payments $2.5 million in near-term payments Double-digit royalties on future net product sales 3.5% equity stake in Intact Therapeutics HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- [...]
Omada Health’s Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks
17/06/2025
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises SAN FRANCISCO, June 17, 2025 (GLOBE [...]
Project Sunshine Announces "Longest Day of Play" Fundraising Campaign Planned for June 20th Alongside Refreshed Visual Identity
17/06/2025
NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Project Sunshine , an organization supporting children and families with medical needs through the power of play, is launching a major fundraising campaign on Friday, June [...]
BioRestorative Announces Share Repurchase Program
17/06/2025
MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based [...]
Prime Biome Gummy: Examining the Science and Safety of a Legal Gut-Skin Health Formula
17/06/2025
LARGO, Fl, June 17, 2025 (GLOBE NEWSWIRE) -- Amid rising interest in gut health and its connection to overall wellness, a new supplement called Prime Biome Gummy has entered the market, offering a science-based approach [...]
FDA Grants Orphan Drug Designation to Medicovestor’s First-in-Class ADC for Pancreatic Cancer
17/06/2025
Novel chemoimmunotherapy platform aims to transform outcomes in one of the world’s deadliest cancers NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Medicovestor , Inc., a biotechnology company advancing next-generation [...]
USAHS & The Brain Center Unite to Support Dementia Caregivers with Hands-On Course
17/06/2025
The event offers immersive training and emotional support for family caregivers during Alzheimer’s & Brain Awareness Month. MIAMI, June 17, 2025 (GLOBE NEWSWIRE) -- In recognition of Alzheimer’s & Brain [...]
Lauréat de l’appel à projet Biothérapies et Bioproduction, du plan France 2030, EVerZom reçoit un financement de l’Etat de 3 millions d’euros pour industrialiser sa technologie de bioproduction d’exosomes
17/06/2025
Lauréat de l’appel à projet Biothérapies et Bioproduction, du plan France 2030, EVerZom reçoit un financement de l’Etat de 3 millions d’euros pour industrialiser sa technologie de bioproduction d’exosomes Paris, le 17 [...]
Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology
17/06/2025
Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology Paris, June 17, 2025 [...]
Astrocyte Pharmaceuticals Announces Milestones in the Fight Against Concussions: Launch of Phase 2 Clinical Trial and New $3M NIH Grant
17/06/2025
GROTON, Conn., June 17, 2025 (GLOBE NEWSWIRE) -- Astrocyte Pharmaceuticals Inc. , a clinical-stage biotechnology company today announced two major milestones that could change the way we protect brains from the damage [...]
AscellaHealth Wins Business Change and Transformation Excellence Award at the Industry Eagles Awards 2025
17/06/2025
DUBLIN and BERWYN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- We are proud to announce that AscellaHealth has been awarded Gold in the Business Change and Transformation Excellence category at the Industry Eagles Awards [...]
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
17/06/2025
- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% [...]
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42
17/06/2025
HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, [...]
Tariffs and U.S.-Canada relations are the top financial concern for seniors: new research from HOOPP and Abacus Data
17/06/2025
TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Geopolitical instability and the ongoing trade dispute with the United States have emerged as a major financial concern for Canadians and is having an impact on people’s [...]
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
17/06/2025
LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25) 71% of patients with complete response [...]
Microbix Attending & Presenting at Asia Pacific POC 2025
17/06/2025
Showcasing Global Utility of its QAPs at Point-of-Care Testing Conference MISSISSAUGA, Ontario, June 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences [...]

Pages